Impact BioMedical Inc. (IBO)
Impact BioMedical Statistics
Share Statistics
Impact BioMedical has 11.5M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 11.5M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 46.55K |
| FTD / Avg. Volume | 0.75% |
Short Selling Information
The latest short interest is -, so null% of the outstanding shares have been sold short.
| Short Interest | - |
| Short % of Shares Out | null% |
| Short % of Float | null% |
| Short Ratio (days to cover) | null |
Valuation Ratios
The PE ratio is -0.63 and the forward PE ratio is null. Impact BioMedical's PEG ratio is 0.
| PE Ratio | -0.63 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Impact BioMedical.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.25, with a Debt / Equity ratio of 0.
| Current Ratio | 0.25 |
| Quick Ratio | 0.25 |
| Debt / Equity | 0 |
| Debt / EBITDA | -3.9 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-12.35K |
| Employee Count | 2 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 33 |
| Effective Tax Rate | -0.13% |
Stock Price Statistics
The stock price has increased by -99.9% in the last 52 weeks. The beta is 7.31, so Impact BioMedical's price volatility has been higher than the market average.
| Beta | 7.31 |
| 52-Week Price Change | -99.9% |
| 50-Day Moving Average | 1.44 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 40.47 |
| Average Volume (20 Days) | 6.18M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -28.75K |
| Net Income | -24.71K |
| EBITDA | -2.28K |
| EBIT | -3.4K |
| Earnings Per Share (EPS) | -2.3 |
Balance Sheet
The company has 2K in cash and 8.88K in debt, giving a net cash position of -6.88K.
| Cash & Cash Equivalents | 2K |
| Total Debt | 8.88K |
| Net Cash | -6.88K |
| Retained Earnings | -37.67K |
| Total Assets | 20.29K |
| Working Capital | -7.34K |
Cash Flow
In the last 12 months, operating cash flow was -3.92M and capital expenditures 0, giving a free cash flow of -3.92M.
| Operating Cash Flow | -3.92M |
| Capital Expenditures | 0 |
| Free Cash Flow | -3.92M |
| FCF Per Share | -364.83 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IBO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for IBO.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -4105.31 |
| Piotroski F-Score | 2 |